AD pathology (amyloidosis and tau neurofibrillary tangles) can be assessed in vivo through cerebrospinal fluid (CSF) biomarkers such as the amyloid-beta 42/40 (Aβ 42/40) ratio and phosphorylated tau (p-tau) (15). The gene discussed is MAPT; the disease is Alzheimer disease.